The pilocarpine model of temporal lobe epilepsy.

Curia G, Longo D, Biagini G, Jones RS, Avoli M. · 2008

Read The pilocarpine model of temporal lobe epilepsy. by Curia G, Longo D, Biagini G, Jones RS, Avoli M. (2008) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2518220.txt.

Introduction

Curia, Longo, Biagini, Jones, and Avoli reviewed in 2008 the pilocarpine model, a standard animal model of temporal lobe epilepsy. In this model, injecting rodents with the drug pilocarpine triggers a long seizure episode. A quiet latent period follows. Finally, spontaneous recurring seizures begin. That sequence mirrors the human disease, which often follows an early injury and involves scarring in the hippocampus, a brain area central to memory.

The authors compared methods across many laboratories, since results shift with rodent species, strain, sex, age, dose, and drug combinations. They weighed death rates, timing of the first spontaneous seizures, neuron damage, and how brain networks rewired under each protocol. They conclude the model stays valuable for studying how epilepsy develops, especially if standardised to cut deaths and reduce variation.

Catalog record

CREATORCuria G, Longo D, Biagini G, Jones RS, Avoli M.
YEAR2008
COLLECTIONPAPERS
FORMATTXT
FILE SIZE100 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2518220

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

The pilocarpine model of temporal lobe epilepsy By Giulia Curia, Daniela Longo, Giuseppe Biagini, Roland S.G. Jones, Massimo Avoli Published in: Journal of Neuroscience Methods DOI: 10.1016/j.jneumeth.2008.04.019 ABSTRACT Understanding the pathophysiogenesis of temporal lobe epilepsy (TLE) largely rests on the use of models of status epilepticus (SE), as in the case of the pilocarpine model. The main features of TLE are: (i) epileptic foci in the limbic system; (ii) an “initial precipitating injury”; (iii) the so-called “latent period”; and (iv) the presence of hippocampal sclerosis leading to reorganization of neuronal networks. Many of these characteristics can be reproduced in rodents by systemic injection of pilocarpine; in this animal model, SE is followed by a latent period and later by the appearance of spontaneous recurrent seizures (SRSs). These processes are, however, influenced by experimental conditions such as rodent species, strain, gender, age, doses and routes of pilocarpine administration, as well as combinations with other drugs administered before and/or after SE. In the attempt to limit these sources of variability, we evaluated the methodological procedures used by several investigators in the pilocarpine model; in particular, we have focused on the behavioural, electrophysiological and histopathological findings obtained with different protocols. We addressed the various experimental approaches published to date, by comparing mortality rates, onset of SRSs, neuronal damage, and network reorganization. Based on the evidence reviewed here, we propose that the pilocarpine model can be a valuable tool to investigate the mechanisms involved in TLE, and even more so when standardized to reduce mortality at the time of pilocarpine injection, differences in latent period duration, variability in the lesion extent, and SRS frequency. INTRODUCTION The ability to reproduce human diseases in animal models presents a great advantage for modern experimental medicine (Russell, 1964). The ideal animal model is homologous, duplicating the human disorder in every respect. Alternatively, the animal model could be isomorphic, when it duplicates the disorder but not the underlying aetiology (that in many neurological diseases is unknown), or predictive, in the case in which it does not resemble the human disorder but allows predictions about it or its response to treatment (this is the case of the kindling paradigm for epilepsy). A great deal of the knowledge that has improved our understanding of epileptic disorders has derived from appropriate animal models (Purpura et al., 1972; Schwartzkroin, 1983; Pitkänen et al., 2006). This is certainly the case in temporal lobe epilepsy (TLE), the most common type of partial complex seizure in adulthood (Hauser et al., 1996; Wieser, 2004). The main features of TLE are: (i) the localization of seizure foci in the limbic system, particularly in the hippocampus, entorhinal cortex and amygdala (Bartolomei et al., 2005); (ii) the frequent finding of an “initial precipitating injury” that precedes the appearance of TLE (Mathern et al., 2002); (iii) a seizure-free time interval following the precipitating injury known as “latent period”; and (iv) a high incidence of mesial or Cornu Ammonis (CA) sclerosis, i.e., a unilateral hippocampal lesion leading to atrophy, typically caused by neuronal loss and gliosis in Sommer's sector (the subiculum-CA1 transition zone) and the endfolium (dentate hilus) (Mathern et al., 1997b). Most of these characteristics can be reproduced in chronic animal models of TLE, particularly kindling or status epilepticus (SE) animal models, which come close to being the ideal homologous model mentioned above (Morimoto et al., 2004). The subject of this review, the pilocarpine model, belongs to SE models. This model appears to be highly isomorphic with the human disease, so it has been used in many laboratories since its first description a quarter of a century ago (Turski et al., 1983a,b). Histopathological findings (Covolan and Mello, 2000) in the pilocarpine model and its use in studying the efficacy of antiepileptic drugs (AEDs; Leite et al., 2002) have been reviewed recently. In this paper we will therefore focus on methodological procedures and the behavioural consequences, especially in view of recent advances in this field made possible by an increasing use of video-electroencephalography (EEG) recordings. Some important features of the pilocarpine model are: (i) the induction of acute SE more rapidly than with intraperitoneal (i.p.) kainic acid, the other convulsant drug commonly used to reproduce TLE in animals; (ii) the presence of a latent period followed by the appearance of spontaneous recurrent seizures (SRSs, chronic phase) (Leite et al., 1990; Cavalheiro et al., 1991); (iii) the occurrence of widespread lesions (see Section 2.3.2), some of them localized in the same brain areas affected in TLE patients, and associated with neuronal network reorganization in hippocampal and parahippocampal regions (for instance, mossy fibre sprouting, interneuron loss and ectopic dentate granule cell proliferation are phenomena shared by TLE patients and pilocarpine-treated animals; Wieser, 2004); (iv) the fact that seizures are poorly controlled by AEDs in patients and pilocarpine-treated epileptic rodents (Glien et al., 2002; Chakir et al., 2006). The ability of pilocarpine to induce SE is likely to depend on activation of the M1 muscarinic receptor subtype, since M1 receptor knockout mice do not develop seizures in response to pilocarpine (Hamilton et al., 1997). Other cholinomimetics, such as carbachol and oxotremorine, are also able to induce seizures and seizure-induced brain damage when injected either systemically or directly into the brain (Olney et al., 1983; Turski et al., 1983b). In addition, pilocarpine-induced SE can be blocked by systemic administration of the muscarinic antagonist atropine (Clifford et al., 1987). Once seizures are initiated, however, their maintenance depends on other mechanisms since atropine becomes ineffective (Clifford et al., 1987). Experiments in cultured hippocampal neurons have demonstrated that pilocarpine, acting through muscarinic receptors, causes an imbalance between excitatory and inhibitory transmission resulting in the generation of SE (Priel and Albuquerque, 2002). In addition, in vivo microdialysis studies have revealed that pilocarpine induces an elevation in glutamate levels in the hippocampus following the appearance of seizures (Smolders et al., 1997). Substantial evidence now supports the suggestion that, following initiation by M1 receptors, seizures are maintained by NMDA receptor activation (Nagao et al., 1996; Smolders et al., 1997). The pilocarpine model is now widely used and it has been modified in a number of laboratories. Depending on the aims of the experiments, different groups of researchers use different dosages of pilocarpine, pretreatment procedures, animal strain and species. In addition, the duration of SE induced by pilocarpine or the drugs employed to terminate it are often inconsistent. These multifaceted protocols could well contribute to the variable findings obtained in different studies. Indeed, the lack of a standardized approach to the pilocarpine model could play a critical role in how it recreates the human scenario. These aspects have recently led some investigators to criticize the pilocarpine model and to propose alternative approaches to reproduce TLE in animals (Sloviter, 2005; Sloviter et al., 2007). In this review we will compare the different protocols used in the pilocarpine model, and in particular to gain consensus as to what factors may be critical in what is perhaps one of the most appropriate models of TLE. BEHAVIOURAL, ELECTROPHYSIOLOGICAL AND HISTOLOGICAL FEATURES Injection of pilocarpine induces a SE that is characterized by tonic–clonic generalized seizures. After several hours of SE, pilocarpine-treated animals remit spontaneously and go into a seizure-free period, known as latent period, before displaying the SRSs

Read the complete text